Longitudinal Study of 21 HGV-Infected Patients
| Patient No. . | Sex/Age at Diagnosis . | Outcome of HGV Infection . | Duration of Viremia (first to last detection date [yr]) . | Duration of Treatment . | Pattern of Development of Anti-E2 . | Modality of Treatment . | Diseases . |
|---|---|---|---|---|---|---|---|
| 1 | F/15 | Clear with anti-E2 | 1989-92 (3) | 1989-90 | − → + → − | CX | NHL |
| 2 | M/8 | Clear without anti-E2 | 1992-95 (3) | 1991-92 | − | CX | NHL |
| 3 | M/4 | Clear without anti-E2 | 1993-96 (3) | 1993-95 | − | rBMT | ALL |
| 4 | F/4 | Clear without anti-E2 | 1993-95 (2) | 1993-94 | − | CX | ALL |
| 5 | F/4 | Clear without anti-E2 | 1993-95 (2) | 1992-93 | − | rBMT | NB |
| 6 | M/13 | Clear without anti-E2 | 1992-94 (2) | 1989-93 | − | rBMT | ALL |
| 7 | F/3 | Persistence of viremia | Before 1987-97 (>10) | 1982-83 | − | CX | ALL |
| 8 | M/2 | Persistence of viremia | 1988-97 (>9) | 1988-90 | − | CX | ALL |
| 9 | F/2 | Persistence of viremia | 1991-97 (>6) | 1990-92 | − | CX | NHL |
| 10 | M/2 | Persistence of viremia | 1991-97 (>6) | 1987-97 | − | CX | ALL |
| 11 | M/3 | Persistence of viremia | 1992-97 (>5) | 1990-92 | − | rBMT | SAA |
| 12 | M/14 | Persistence of viremia | 1993-97 (>4) | 1992-97 | − → + → − | uBMT | ALL |
| 13 | M/8 | Persistence of viremia | 1993-97 (>4) | 1992-97 | + → − | CX | ALL |
| 14 | F/11 | Persistence of viremia | 1993-97 (>3) | 1993-96 | − | uBMT | AML |
| 15 | F/6 | Persistence of viremia | 1993-96 (>3) | 1993-94 | − | CX | ALL |
| 16 | F/4 | Died with positive HGV-RNA | Before 1987-97 (>10) | 1984-97 | − | aBMT | ALL |
| 17 | M/6 | Died with positive HGV-RNA | Before 1987-93 (>6) | 1985-93 | − | CX | ALL |
| 18 | F/3 | Died with positive HGV-RNA | Before 1987-93 (>6) | 1986-93 | − | CX | ALL |
| 19 | M/8 | Died with positive HGV-RNA | 1991-94 (3) | 1990-94 | − | uBMT | AML |
| 20 | F/11 | Died with positive HGV-RNA | 1993-94 (1) | 1992-94 | − | aBMT | ALL |
| 21 | M/11 | Acquired anti-E2 before transfusion | — (0) | 1993-95 | + | CX | ALL |
| Patient No. . | Sex/Age at Diagnosis . | Outcome of HGV Infection . | Duration of Viremia (first to last detection date [yr]) . | Duration of Treatment . | Pattern of Development of Anti-E2 . | Modality of Treatment . | Diseases . |
|---|---|---|---|---|---|---|---|
| 1 | F/15 | Clear with anti-E2 | 1989-92 (3) | 1989-90 | − → + → − | CX | NHL |
| 2 | M/8 | Clear without anti-E2 | 1992-95 (3) | 1991-92 | − | CX | NHL |
| 3 | M/4 | Clear without anti-E2 | 1993-96 (3) | 1993-95 | − | rBMT | ALL |
| 4 | F/4 | Clear without anti-E2 | 1993-95 (2) | 1993-94 | − | CX | ALL |
| 5 | F/4 | Clear without anti-E2 | 1993-95 (2) | 1992-93 | − | rBMT | NB |
| 6 | M/13 | Clear without anti-E2 | 1992-94 (2) | 1989-93 | − | rBMT | ALL |
| 7 | F/3 | Persistence of viremia | Before 1987-97 (>10) | 1982-83 | − | CX | ALL |
| 8 | M/2 | Persistence of viremia | 1988-97 (>9) | 1988-90 | − | CX | ALL |
| 9 | F/2 | Persistence of viremia | 1991-97 (>6) | 1990-92 | − | CX | NHL |
| 10 | M/2 | Persistence of viremia | 1991-97 (>6) | 1987-97 | − | CX | ALL |
| 11 | M/3 | Persistence of viremia | 1992-97 (>5) | 1990-92 | − | rBMT | SAA |
| 12 | M/14 | Persistence of viremia | 1993-97 (>4) | 1992-97 | − → + → − | uBMT | ALL |
| 13 | M/8 | Persistence of viremia | 1993-97 (>4) | 1992-97 | + → − | CX | ALL |
| 14 | F/11 | Persistence of viremia | 1993-97 (>3) | 1993-96 | − | uBMT | AML |
| 15 | F/6 | Persistence of viremia | 1993-96 (>3) | 1993-94 | − | CX | ALL |
| 16 | F/4 | Died with positive HGV-RNA | Before 1987-97 (>10) | 1984-97 | − | aBMT | ALL |
| 17 | M/6 | Died with positive HGV-RNA | Before 1987-93 (>6) | 1985-93 | − | CX | ALL |
| 18 | F/3 | Died with positive HGV-RNA | Before 1987-93 (>6) | 1986-93 | − | CX | ALL |
| 19 | M/8 | Died with positive HGV-RNA | 1991-94 (3) | 1990-94 | − | uBMT | AML |
| 20 | F/11 | Died with positive HGV-RNA | 1993-94 (1) | 1992-94 | − | aBMT | ALL |
| 21 | M/11 | Acquired anti-E2 before transfusion | — (0) | 1993-95 | + | CX | ALL |
Abbreviations: CX, chemotherapy; rBMT, related allogeneic bone marrow transplantation; uBMT, unrelated allogeneic bone marrow transplantation; aBMT, autologous bone marrow transplantation.